Attached files
| file | filename |
|---|---|
| 10-K/A - AMENDMENT NO. 1 - Tribute Pharmaceuticals Canada Inc. | tbuff_10ka.htm |
| EX-32.1 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc. | tbuff_ex321.htm |
| EX-31.2 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc. | tbuff_ex312.htm |
| EX-31.1 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc. | tbuff_ex311.htm |
| EX-10.37 - LOAN AND SECURITY AGREEMENT - Tribute Pharmaceuticals Canada Inc. | tbuff_ex1037.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with Amendment No. 1 to the Annual Report of Tribute Pharmaceuticals Canada Inc. (the "Company") on Form 10-K/A for the year ended December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Scott Langille, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
June 5, 2013
|
By:
|
/s/ Scott Langille
|
|
|
Scott Langille
|
|||
|
Chief Financial Officer
|